Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0000578

Paroxetine hydrochloride (anhydrous)

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Paroxetine hydrochloride, (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H20FNO3 · HCl
CAS Number:
78246-49-8
Molecular Weight:
365.83
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

paroxetine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C19H20FNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7-8,10-12H2;1H/t14-,17-;/m0./s1

InChI key

GELRVIPPMNMYGS-RVXRQPKJSA-N

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paroxetine hydrochloride (anhydrous) EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000630

Paroxetine for system suitability, European Pharmacopoeia (EP) Reference Standard

1500218

Paroxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000581

Paroxetine hydrochloride (anhydrous) impurity H, European Pharmacopoeia (EP) Reference Standard

Y0000233

Paroxetine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000281

Paroxetine hydrochloride hemihydrate, European Pharmacopoeia (EP) Reference Standard

1500353

Paroxetine System Suitability Mixture A, United States Pharmacopeia (USP) Reference Standard

Y0000580

Paroxetine impurity E, European Pharmacopoeia (EP) Reference Standard

1500230

Paroxetine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1500240

Paroxetine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1500251

Paroxetine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1500284

Paroxetine Related Compound G, United States Pharmacopeia (USP) Reference Standard, ~21% povidone

Y0000579

Paroxetine hydrochloride (anhydrous) impurity C, European Pharmacopoeia (EP) Reference Standard

PHR1804

Paroxetine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP1024

Paroxetine hydrochloride hemihydrate, British Pharmacopoeia (BP) Reference Standard

BP746

Paroxetine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR3076

Paroxetine Related Compound C, pharmaceutical secondary standard, certified reference material

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mats B Humble et al.
BMC psychiatry, 13, 344-344 (2013-12-24)
The drug treatments of choice for obsessive-compulsive disorder (OCD) are serotonin reuptake inhibitors (SRIs). However, a correlation between the neuropeptide oxytocin in cerebrospinal fluid and the severity of OCD has previously been shown, and oxytocin and serotonin are interconnected within
N E Ordyan et al.
Patologicheskaia fiziologiia i eksperimental'naia terapiia, (4)(4), 64-67 (2014-03-20)
The aim of the present work was an estimation of effects of chronic administration of selective serotonin reuptake inhibitors--fluoxetine (5.0 mg/kg, p.o.) and paroxetine (5.0 mg/kg, p.o.) for 14 days of postnatal period on anxiety-like behavior in the prenatally stressed
Huang-Li Lin et al.
International clinical psychopharmacology, 28(6), 339-345 (2013-07-25)
This is a single-blind, parallel, flexible-dose study to compare the efficacy and tolerability of escitalopram and paroxetine in the treatment of patients with major depressive disorder. We recruited 399 patients from the outpatient clinics of five hospitals in northern Taiwan.
Marek Krzystanek et al.
Pharmacological reports : PR, 65(3), 724-729 (2013-08-21)
Phospholipase D (PLD) plays a key role in a second messenger system producing phosphatidic acid, mediating, among others, serotonin 5-HT2 receptor activity. The aim of the study was to evaluate a possible effect of atypical antipsychotic drug, olanzapine (OLZ), and
Pleuropulmonary complications related to pulmonary instillation of activated charcoal.
Luiz Felipe Nobre et al.
Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 39(3), 396-397 (2013-07-17)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service